Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23874527 | 0.90 | AURKA (0.43) | GLSKDM4ANPC1KCNA5DYRK1A | |
| SCHEMBL23874457 | 0.88 | GLS (0.39) | GLSKDM4AHPGDKCNA5DYRK1A | |
| SCHEMBL30466622 | 0.85 | GAA (0.46) | GLSKDM4ANPC1HPGD | |
| SCHEMBL28366626 | 0.85 | GAA (0.46) | GLSKDM4ANPC1HPGD | |
| SCHEMBL28371117 | 0.85 | KDM4A (0.41) | GLSKDM4AHPGDNQO2CYP1A2 | |
| SCHEMBL30466599 | 0.85 | KDM4A (0.41) | GLSKDM4AHPGDNQO2CYP1A2 | |
| SCHEMBL23874407 | 0.85 | KDM4A (0.41) | GLSKDM4AHPGDNQO2KCNA5 | |
| SCHEMBL30466623 | 0.85 | GAA (0.46) | GLSKDM4ANPC1HPGD | |
| SCHEMBL4159541 | 0.79 | HPGD (0.55) | KDM4ANPC1HPGDCYP1A2POLB | |
| SCHEMBL27006560 | 0.79 | NAMPT (0.43) | CA12CA1CYP1A2CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ANTABIO SAS (FR) | 2025-03-11 | — | — | US | disclosed |
| CN-113166084-B | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| US-20240016941-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4125883-A1 | COMBINATION THERAPY | Antabio SAS (FR) | 2023-02-08 | — | — | EP | disclosed |
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ANTABIO SAS (FR) | 2022-04-14 | — | — | US | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021191240-A1 | COMBINATION THERAPY | ANTABIO SAS (FR) | 2021-09-30 | — | — | WO | disclosed |
| CN-113166084-A | Indane derivatives for the treatment of bacterial infections | 安塔比奥公司 | 2021-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112169-A1 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | ARG1, ELANE, INSR | GLS 1758/4885KDM4A 3726/4885NPC1 782/4885 |
| US-20240016941-A1 | COMBINATION THERAPY | CFTR, ABCB11, SLC26A4 | GLS 524/4885KDM4A 4502/4885NPC1 81/4885 |
| US-12247013-B2 | Indane derivatives for use in the treatment of bacterial infection | ELANE, ARG1, INSRR | GLS 2139/4885KDM4A 3796/4885NPC1 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.